IntravenousCommunity-acquired pneumoniaAdult: Initially, 100 mg as a single dose followed by 50 mg 12 hrly for 7-14 days. Infuse dose over 30-60 min.
IntravenousComplicated intra-abdominal infections, Complicated skin and skin structure infectionsAdult: 100 mg as a single dose, followed by 50 mg 12 hrly for 5-14 days. Infuse dose over 30-60 min.
|
No dosage adjustment needed.
|
Mild to moderate: No dosage adjustment. Severe: 100 mg as a single dose, then 25 mg 12 hrly.
|
Reconstitute 50 mg vial w/ 5.3 mL of NaCl 0.9% inj or dextrose 5% inj or Lactate Ringer's inj to achieve a concentration of 10 mg/mL. For IV bag infusion: Further dilute a 5 mL reconstituted soln w/ 100 mL of IV bag for infusion. For a 100 mg dose: Reconstitute two 50 mg vials and dilute 10 mL of the reconstituted soln in 100 mL of IV infusion soln. For a 50 mg dose: Further dilute a 5 mL reconstituted soln w/ 100 mL of NaCl 0.9% inj or dextrose 5% inj. Concentration of infused soln should not exceed 1 mg/mL. The reconstituted soln should be yellow to orange only.
|
Y-site: Amphotericin B, amphotericin B lipid complex, diazepam, omeprazole , esomeprazole or any IV soln that may result in a pH above 7.
|
Hypersensitivity. Hospital-acquired pneumonia and ventilator-associated pneumonia. Use during tooth development.
|
Hypersensitivity to tetracyclines. Use tigecycline in situations when alternative treatments are not suitable. Patients w/ complicated intra-abdominal infections secondary to clinically apparent intestinal perforation. Hepatic impairment. Pregnancy and lactation.
|
Nausea, vomiting, diarrhoea, abdominal pain, anorexia, headache, dizziness, jaundice, abscess, dyspepsia, acidosis, hypoproteinemia, thrombophlebitis, photosensitivity, inj site reactions, pruritus, rash, overgrowth of nonsusceptible organisms (e.g. fungi), Clostridium-difficile associated diarrhoea, prolonged prothrombin time (PT) and aPTT increased ALT, AST, alkaline phosphatase and bilirubin.
Potentially Fatal: Sepsis or septic shock. Anaphylaxis and anaphylactoid reactions. Acute pancreatitis. Fatal colitis. Liver impairment w/ fatal liver failure.
|
|
Increased warfarin serum levels. May decrease efficacy of oral contraceptives.
|
Description: Tigecycline is a glycylcycline antibiotic which prevents protein synthesis of the susceptible bacteria by binding to its 30s ribosomal subunit. It is generally considered as bacteriostatic agent; w/ bactericidal activity against S. pneumonia and L. pneumophilia. Tigecycline antibacterial activity covers facultative gm+ve (including MRSA, vancomycin-susceptible Enterococcus faecalis) and gm-ve bacteria, and anaerobic bacteria. Pharmacokinetics: Absorption: Bioavailability: 100%. Distribution: Widely distributed; crosses the placenta. Volume of distribution: 7-9 L/kg. Plasma protein binding: 71-89%. Metabolism: Not extensively metabolised, resulting in trace amount of glucuronide, N-acetyl metabolite and tigecycline epimer. Excretion: Via faeces: 60% (mainly as unchanged drug); urine: 33% (approx 22% as unchanged drug). Elimination half-life: 42 hr (following multiple doses).
|
Unopened vial: Store between 20-25°C. Reconstituted soln: 24 hr at room temperature (up to 6 hr in vial). IV infusion bag diluted w/ NaCl 0.9% inj or dextrose 5% inj: 48 hr between 2-8°C.
|
|
Anon. Tigecycline. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 11/11/2013. Buckingham R (ed). Tigecycline. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/11/2013. Joint Formulary Committee. Tigecycline. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/11/2013. McEvoy GK, Snow EK, Miller J et al (eds). Tigecycline. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 11/11/2013. Tygacil (tigecycline): Drug Safety Communication - Increased Risk of Death. U.S. FDA. https://www.fda.gov/. Accessed 11/11/2013.
|